Pathogens and Immunity最新文献

{"title":"Raymond Schinazi Discusses the Discovery of Early Antiretroviral Agents and Sofosbuvir.","authors":"Michael M Lederman, Neil S Greenspan","doi":"10.20411/pai.v8i1.624","DOIUrl":"https://doi.org/10.20411/pai.v8i1.624","url":null,"abstract":"","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":"8 1","pages":"77-92"},"PeriodicalIF":0.0,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664204/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138465439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Evolution of Diagnostic Techniques in the Paleopathology of Tuberculosis: A Scoping Review.","authors":"Veronica Papa,&nbsp;Francesco M Galassi,&nbsp;Elena Varotto,&nbsp;Andrea Gori,&nbsp;Mauro Vaccarezza","doi":"10.20411/pai.v8i1.597","DOIUrl":"https://doi.org/10.20411/pai.v8i1.597","url":null,"abstract":"<p><p>Tuberculosis (TB) is an ancient chronic infectious disease that remains a global health concern. In human remains, the most common and characteristic clinical signs are the skeletal modifications involving the spine, such as in Pott's disease. Diagnosing TB in ancient human remains is challenging. Therefore, in this systematic review, the authors investigated the studies assessing molecular diagnosis of Pott's disease in ancient human remains with the intention to survey the literature, map the evidence, and identify gaps and future perspectives on TB in paleopathology. Our systematic review offers a full contextualization of the history of Pott's disease in ancient times. Our search strategy was performed between August 2022 and March 2023. The authors initially identified 340 records, and 74 studies were finally included and assessed for qualitative analysis. Due to non-specific clinical signs associated with TB, how best to diagnose tuberculosis in human remains still represents a central point. Nevertheless, ancient DNA (aDNA) analysis, lipid biomarkers, and spoligotyping might be extremely useful tools in the study of TB in human remains. Moreover, we propose the extraction and study of immune response genes involved in innate and adaptive immunity versus <i>Mycobacterium spp</i>. as an innovative and vastly overlooked approach in TB paleopathology. Complementary methodologies should be integrated to provide the best approach to the study of TB in human remains.</p>","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":"8 1","pages":"93-116"},"PeriodicalIF":0.0,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603826/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71414461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic Characterization of 2 <i>Cutibacterium acnes</i> Isolates from a Surgical Site Infection Reveals Large Genomic Inversion.","authors":"D Garrett Brown,&nbsp;Taylor A Wahlig,&nbsp;Angela Ma,&nbsp;Laura K Certain,&nbsp;Peter N Chalmers,&nbsp;Mark A Fisher,&nbsp;Daniel T Leung","doi":"10.20411/pai.v8i1.606","DOIUrl":"10.20411/pai.v8i1.606","url":null,"abstract":"<p><strong>Background: </strong><i>Cutibacterium acnes</i> is a common commensal of human skin but may also present as an opportunistic pathogen in prosthetic joint and wound infections. Unfortunately, few complete genomes of <i>C. acnes</i> are publicly available, and even fewer are of isolates associated with infection. Here we report the isolation, characterization, and complete genomes of 2 <i>C. acnes</i> isolates from a surgical site infection of an elbow.</p><p><strong>Methods: </strong>We used standard microbiological methods for phenotypic characterization and performed whole genome sequencing on 2 <i>C. acnes</i> isolates using a combination of short-read and long-read sequencing.</p><p><strong>Results: </strong>Antibiotic susceptibility testing showed beta-lactamase negative and low minimal inhibitory concentrations to all antibiotics tested, with the exception of metronidazole. We assembled complete genomes of the 2 isolates, which are approximately 2.5 megabases in length. The isolates belong to the single-locus sequence type (SLST) H1 and the multi-locus sequence type (MLST) IB. Both isolates have similar composition of known virulence genes, and we found no evidence of plasmids but did find phage-associated genes. Notably, the 2 genomes are 99.97% identical but contain a large genomic inversion encompassing approximately half of the genome.</p><p><strong>Conclusions: </strong>This is the first characterization of this large-scale genomic inversion in nearly identical isolates from the same wound. This report adds to the limited numbers of publicly available infection-associated complete genomes of <i>C. acnes</i>.</p>","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":"8 1","pages":"64-76"},"PeriodicalIF":0.0,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41214989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Military Medicine and Medical Research as a Source of Inspiration and Innovation to Solve National Security and Health Challenges in the 21st Century.","authors":"Nanak S Dhillon,&nbsp;Nayeon Jeon,&nbsp;Umut A Gurkan,&nbsp;Anirban Sen Gupta,&nbsp;Robert A Bonomo,&nbsp;Lawrence F Drummy,&nbsp;Mei Zhang,&nbsp;Mark R Chance","doi":"10.20411/pai.v8i1.596","DOIUrl":"10.20411/pai.v8i1.596","url":null,"abstract":"<p><p>The history of military medicine and research is rife with examples of novel treatments and new approaches to heal and cure soldiers and others impacted by war's devastation. In the 21st century, new threats, like climate change, are combined with traditional threats, like geopolitical conflict, to create novel challenges for our strategic interests. Extreme and inaccessible environments provide heightened risks for warfighter exposure to dangerous bacteria, viruses, and fungi, as well as exposure to toxic substances and extremes of temperature, pressure, or both providing threats to performance and eroding resilience. Back home, caring for our veterans is also a health-care priority, and the diseases of veterans increasingly overlap with the health needs of an aging society. These trends of climate change, politics, and demographics suggest performance evaluation and resilience planning and response are critical to assuring both warfighter performance and societal health. The Cleveland ecosystem, comprising several hospitals, a leading University, and one of the nation's larger Veteran's Health Administration systems, is ideal for incubating and understanding the response to these challenges. In this review, we explore the interconnections of collaborations between Defense agencies, particularly Air Force and Army and academic medical center-based investigators to drive responses to the national health security challenges facing the United States and the world.</p>","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":"8 1","pages":"51-63"},"PeriodicalIF":0.0,"publicationDate":"2023-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550252/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41151310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunohematologic Biomarkers in COVID-19: Insights into Pathogenesis, Prognosis, and Prevention.","authors":"David R Sweet,&nbsp;Michael L Freeman,&nbsp;David A Zidar","doi":"10.20411/pai.v8i1.572","DOIUrl":"10.20411/pai.v8i1.572","url":null,"abstract":"<p><p>Coronavirus disease 2019 (COVID-19) has had profound effects on the health of individuals and on healthcare systems worldwide. While healthcare workers on the frontlines have fought to quell multiple waves of infection, the efforts of the larger research community have changed the arch of this pandemic as well. This review will focus on biomarker discovery and other efforts to identify features that predict outcomes, and in so doing, identify possible effector and passenger mechanisms of adverse outcomes. Identifying measurable soluble factors, cell-types, and clinical parameters that predict a patient's disease course will have a legacy for the study of immunologic responses, especially stimuli, which induce an overactive, yet ineffectual immune system. As prognostic biomarkers were identified, some have served to represent pathways of therapeutic interest in clinical trials. The pandemic conditions have created urgency for accelerated target identification and validation. Collectively, these COVID-19 studies of biomarkers, disease outcomes, and therapeutic efficacy have revealed that immunologic systems and responses to stimuli are more heterogeneous than previously assumed. Understanding the genetic and acquired features that mediate divergent immunologic outcomes in response to this global exposure is ongoing and will ultimately improve our preparedness for future pandemics, as well as impact preventive approaches to other immunologic diseases.</p>","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":"8 1","pages":"17-50"},"PeriodicalIF":0.0,"publicationDate":"2023-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324469/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9801095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Community-Driven Framework to Prioritize the Use of Donated Human Biological Materials in the Context of HIV Cure-Related Research at the End of Life.","authors":"Karine Dubé, Thomas J Villa, Jeff Taylor, Andy Kaytes, David J Moore, Susan J Little, Antoine Chaillon, Davey M Smith, Sara Gianella","doi":"10.20411/pai.v8i1.583","DOIUrl":"10.20411/pai.v8i1.583","url":null,"abstract":"<p><p>Initiated in 2017 after extensive community engagement, the Last Gift program enrolls altruistic volunteers willing to donate their cells and tissues at the end of life to allow studies on HIV reservoir dynamics across anatomical sites. As the Last Gift team received tissue requests outside the scope of HIV cure research, we noticed the absence of guiding frameworks to help prioritize the use of altruistically donated human biological materials. In this commentary, we present a proposed framework for prioritizing the use of donated human biological materials within and outside the end-of-life (EOL) HIV cure research context, using the Last Gift study as an example. First, we discuss regulatory and policy considerations, and highlight key ethical values to guide prioritization decisions. Second, we present our prioritization framework and share some of our experiences prioritizing requests for donated human biological materials within and outside EOL HIV cure research.</p>","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":"8 1","pages":"1-16"},"PeriodicalIF":0.0,"publicationDate":"2023-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225111/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9586919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"B-Cell Responses to Sars-Cov-2 mRNA Vaccines.","authors":"Lela Kardava,&nbsp;Clarisa M Buckner,&nbsp;Susan Moir","doi":"10.20411/pai.v7i2.550","DOIUrl":"10.20411/pai.v7i2.550","url":null,"abstract":"<p><p>Most vaccines against viral pathogens protect through the acquisition of immunological memory from long-lived plasma cells that produce antibodies and memory B cells that can rapidly respond upon an encounter with the pathogen or its variants. The COVID-19 pandemic and rapid deployment of effective vaccines have provided an unprecedented opportunity to study the immune response to a new yet rapidly evolving pathogen. Here we review the scientific literature and our efforts to understand antibody and B-cell responses to SARS-CoV-2 vaccines, the effect of SARSCoV-2 infection on both primary and secondary immune responses, and how repeated exposures may impact outcomes.</p>","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":"7 2","pages":"93-119"},"PeriodicalIF":0.0,"publicationDate":"2022-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9836209/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9114880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pandemics and the English Language: Concepts Critical for Conversing About COVID-19.","authors":"Neil S Greenspan,&nbsp;Guillermo A Pereda","doi":"10.20411/pai.v7i2.542","DOIUrl":"https://doi.org/10.20411/pai.v7i2.542","url":null,"abstract":"<p><p>We consider the multiple senses of several key terms that are used to discuss the ongoing COVID-19 pandemic and clarify meanings of the corresponding concepts. Topics addressed include: 1) the meaning of immunity to an infectious agent in varying medical and scientific contexts, 2) the scientific factors that influenced the rapid generation and clinical implementation of safe and effective vaccines for COVID-19, 3) the difference between mutational abrogation of reactivity with B- or T-cell antigen receptors (immune escape) versus active interference with host immune mechanisms mediated by gene products encoded within the genome of the infectious agent (immune evasion), 4) the different ways by which the COVID-19 pandemic has \"caused\" deaths, and 5) briefly, the challenge of precisely defining the term <i>pathogen</i>.</p>","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":" ","pages":"78-92"},"PeriodicalIF":0.0,"publicationDate":"2022-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40699733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Evidence on the Effectiveness of Plexiglass Barriers in Reducing Aerosol Exposure.","authors":"Jennifer L Cadnum,&nbsp;Annette L Jencson,&nbsp;Samir Memic,&nbsp;Andrew O Osborne,&nbsp;Maria M Torres-Teran,&nbsp;Brigid M Wilson,&nbsp;Abhishek Deshpande,&nbsp;Curtis J Donskey","doi":"10.20411/pai.v7i2.533","DOIUrl":"https://doi.org/10.20411/pai.v7i2.533","url":null,"abstract":"<p><p>\u0000 <i>Reprinted with permission, Cleveland Clinic Foundation ©2022. All Rights Reserved.</i>\u0000 </p><p><strong>Background: </strong>Barriers are commonly installed in workplace situations where physical distancing cannot be maintained to reduce the risk for transmission of respiratory viruses. Although some types of barriers have been shown to reduce exposure to aerosols in laboratory-based testing, limited information is available on the efficacy of barriers in real-world settings.</p><p><strong>Methods: </strong>In an acute care hospital, we tested the effectiveness of in-use plexiglass barriers in reducing exposure of staff to aerosolized particles. A nebulizer was used to release 5% NaCl aerosol 1 meter from staff members with and without the barrier positioned between the point of aerosol release and the hospital staff. Particle counts on the staff side of the barrier were measured using a 6-channel particle counter. A condensed moisture (fog) generating device was used to visualize the airflow patterns.</p><p><strong>Results: </strong>Of 13 in-use barriers tested, 6 (46%) significantly reduced aerosol particle counts detected behind the barrier, 6 (46%) reduced particle counts to a modest, non-significant degree, and 1 (8%) significantly increased particle counts behind the barrier. Condensed moisture fog accumulated in the area where staff were seated behind the barrier that increased particle exposure, but not behind the other barriers. After repositioning the ineffective barrier, the condensed moisture fog no longer accumulated behind the barrier and aerosol exposure was reduced.</p><p><strong>Conclusion: </strong>In real-world settings, plexiglass barriers vary widely in effectiveness in reducing staff exposure to aerosols, and some barriers may increase risk for exposure if not positioned correctly. Devices that visualize airflow patterns may be useful as simple tools to assess barriers.</p>","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":" ","pages":"66-77"},"PeriodicalIF":0.0,"publicationDate":"2022-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9651177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40687274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans.","authors":"Panagiotis Zagaliotis, Jordyn Michalik-Provasek, Jason J Gill, Thomas J Walsh","doi":"10.20411/pai.v7i2.516","DOIUrl":"10.20411/pai.v7i2.516","url":null,"abstract":"<p><p>Drug-resistant Gram-negative bacterial pathogens are an increasingly serious health threat causing worldwide nosocomial infections with high morbidity and mortality. Of these, the most prevalent and severe are <i>Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii,</i> and <i>Salmonella typhimurium.</i> The extended use of antibiotics has led to the emergence of multidrug resistance in these bacteria. Drug-inactivating enzymes produced by these bacteria, as well as other resistance mechanisms, render drugs ineffective and make treatment of such infections more difficult and complicated. This makes the development of novel antimicrobial agents an urgent necessity. Bacteriophages, which are bacteria-killing viruses first discovered in 1915, have been used as therapeutic antimicrobials in the past, but their use was abandoned due to the widespread availability of antibiotics in the 20th century. The emergence, however, of drug-resistant pathogens has re-affirmed the need for bacteriophages as therapeutic strategies. This review describes the use of bacteriophages as novel agents to combat this rapidly emerging public health crisis by comprehensively enumerating and discussing the innovative use of bacteriophages in both animal models and in patients infected by Gram-negative bacteria.</p>","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":" ","pages":"1-45"},"PeriodicalIF":0.0,"publicationDate":"2022-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40438666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}